Cargando…

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys

BACKGROUND: Inhibition of activated factor XI (FXIa) is a promising antithrombotic drug target. BMS‐724296 is a selective, reversible, small‐molecule inhibitor of human FXIa (K(i) 0.3 nM). OBJECTIVES: This study assessed effects of BMS‐724296 versus standard‐of‐care oral anticoagulants apixaban (act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Pancras C., Quan, Mimi L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162232/ https://www.ncbi.nlm.nih.gov/pubmed/34095733 http://dx.doi.org/10.1002/rth2.12524

Ejemplares similares

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014)

Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)
Publicado: (2010)

Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
por: Grossmann, Klaus
Publicado: (2021)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
por: Salta, Stella, et al.
Publicado: (2018)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis
por: Yang, Yi-Yao, et al.
Publicado: (2020)

Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa
por: Kar, Srabani, et al.
Publicado: (2021)

Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
por: Jones, Aaryana, et al.
Publicado: (2023)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Comparative Thrombin Generation in Animal Plasma: Sensitivity to Human Factor XIa and Tissue Factor
por: Liang, Yideng, et al.
Publicado: (2023)

Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides
por: Al-Horani, Rami A., et al.
Publicado: (2014)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans
por: Piel, Isabel, et al.
Publicado: (2023)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

LC–MS-based multivariate statistical analysis for the screening of potential thrombin/factor Xa inhibitors from Radix Salvia Miltiorrhiza
por: Yang, Yi-Yao, et al.
Publicado: (2020)

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
por: Liu, Zhiyan, et al.
Publicado: (2022)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa
por: Novichikhina, Nadezhda, et al.
Publicado: (2020)

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2021)

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances
por: Xia, Yunqing, et al.
Publicado: (2023)

Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model
por: Hosokawa, Kazuya, et al.
Publicado: (2014)

Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen–Chuanxiong Herbal Pair through a Spectrum–Effect Relationship Analysis
por: Wang, Xu, et al.
Publicado: (2021)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
por: Shaw, Joseph R., et al.
Publicado: (2023)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_438s8fs1t0cuo7rn4n372v29c5